NDA 209195 · Gilead Sciences INC
Vosevi
Sofosbuvir, Velpatasvir, Voxilaprevir · Oral · Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor; Hepatitis C Virus NS5A Inhibitor; Hepatitis C Virus NS3/4A Protease Inhibitor
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Nov 15, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2017
Jul 18, 2017
Approved uses
2
Original approval plus efficacy supplements
Registered trials
343
110 Phase 3, 6 recruiting
FAERS reports
1,086
405 serious, 35 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN PATIENTS COINFECTED WITH HCV AND HBV Test all patients for evidence of current or prior hepatitis B virus (HBV) infection before initiating treatment with VOSEVI. HBV reactivation has been reported in HCV/HBV coinfected patients who were undergoing or had completed treatment with HCV direct-acting antivirals (DAA) and were not receiving HBV antiviral therapy. Some cases have resulted in fulminant hepatitis, hepatic failure, and death. Monitor HCV/HBV coinfected patients for hepatitis flare or HBV reactivation during HCV treatment and post-treatment follow-up. Initiate appropriate patient management for HBV infection as clinically indicated [see Warnings and Precautions (5.1) ]. WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN PATIENTS COINFECTED WITH HCV AND HBV See full prescribing information for complete boxed warning. Hepatitis B...
What it is approved for
From the label in effect Jul 14, 2025.
VOSEVI is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis (Child-Pugh A) who have [see Dosage and Administration (2.2) and Clinical Studies (14) ]: genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an HCV regimen containing an NS5A inhibitor. genotype 1a or 3 infection and have previously been treated with an HCV regimen containing sofosbuvir without an NS5A inhibitor. Additional benefit of VOSEVI over sofosbuvir/velpatasvir was not shown in adults with genotype 1b, 2, 4, 5, or 6 infection previously treated with sofosbuvir without an NS5A inhibitor. VOSEVI is a fixed-dose combination of sofosbuvir, a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor, velpatasvir, an HCV NS5A inhibitor, and voxilaprevir, an HCV NS3/4A protease inhibitor, and is indicated for the treatment of adult patients with chronic HCV infection without cirrhosis or with compensated cirrhosis (Child-Pugh A) who have ( 1 , 2.2 , 14 ): genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an HCV regimen containing an NS5A inhibitor. genotype 1a or 3 infection and have previously been treated with an HCV regimen containing sofosbuvir without an NS5A inhibitor. Additional benefit of VOSEVI over sofosbuvir/velpatasvir was not shown in adults with genotype 1b, 2, 4, 5, or 6 infection previously treated with sofosbuvir without an NS5A inhibitor.
Mechanism: VOSEVI is a fixed-dose combination of sofosbuvir, velpatasvir, and voxilaprevir which are DAA agents against the hepatitis C virus [see Microbiology (12.4) ].
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 15, 2019 Supplement 3 · Efficacy LetterLabel
- Jul 18, 2017 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination · priority review NovelLabelLetterReview
1 products under this application
- VOSEVI · SOFOSBUVIR 400MG; VELPATASVIR 100MG; VOXILAPREVIR 100MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Sofosbuvir" as an intervention, any sponsor and status, largest first.
- Management of Patients With Hepatitis C in a Public Health Care Setting: The Punjab ModelStatus unknown
Post Graduate Institute of Medical Education and Research, ChandigarhAcademic, hospital or other
NCT03488485 · 50,000 participants (planned) · Start Jun 18, 2016 · Primary completion Dec 2020
Drug: Direct Acting Antivirals · For: Chronic Hepatitis c
Sites: Chandigarh, India
- Safety and Efficacy of Decentralized HCV Treatment vs Standard-of-Care in Rio de Janeiro (Brazil)Pivotal-lookingRecruiting
Oswaldo Cruz FoundationAcademic, hospital or other
NCT06306300 · 30,000 participants (planned) · Start Jul 4, 2022 · Primary completion Dec 31, 2026
Drug: Specialist - Epclusa 400Mg-100Mg Tablet; Non- specialist - Epclusa 400Mg-100Mg Tablet · For: Hepatitis C
Sites: Rio de Janeiro, Brazil · 2 sites in all
- Study of DAA Treatment for Children and Adolescents With Active HCV Infection in CambodiaActive, not recruiting
ANRS, Emerging Infectious DiseasesGovernment (non-federal)
NCT05992077 · 21,000 participants (planned) · Start Aug 7, 2023 · Primary completion Jan 31, 2026
Drug: Sofosbuvir/Daclatasvir · For: HCV Infection
Sites: Battambang, Cambodia; Phnom Penh, Cambodia; Siem Reap, Cambodia · 4 sites in all
- Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C InfectionPivotal-lookingCompleted
Tanta UniversityAcademic, hospital or other
NCT02992457 · 10,000 participants · Start Jan 2015 · Primary completion Dec 2018
Drug: Sofosbuvir; Ribavirin and 6 more · For: Hepatitis C
Sites: Tanta, Egypt · 2 sites in all
Kirby InstituteGovernment (non-federal)
NCT02064049 · 3,692 participants · Start Oct 2014 · Primary completion Nov 2019
Drug: Sofosbuvir/velpatasvir · For: Hepatitis C
Sites: Goulburn, Australia; Lithgow, Australia; Windsor, Australia · 4 sites in all
- Simplifying Hepatitis C Pathways for People Who Inject Drugs in Armenia, Georgia, and TanzaniaRecruiting
Médecins du MondeAcademic, hospital or other
NCT06159504 · 3,040 participants (planned) · Start Oct 3, 2024 · Primary completion Dec 2026
Drug: sofosbuvir/velpatasvir (SOF/VEL) · For: Hepatitis C; RDT
Sites: Yerevan, Armenia
- COVID-19 Prophylaxis South Africa (COVER HCW)Pivotal-lookingCompleted
University of Witwatersrand, South AfricaAcademic, hospital or other
NCT04561063 · 1,950 participants · Start Dec 8, 2020 · Primary completion Feb 28, 2022
Drug: Nitazoxanide; Sofosbuvir/Daclatasvir · For: Covid19; SARS-CoV Infection
Sites: Johannesburg, South Africa · 2 sites in all
- Same-visit Hepatitis C Testing and Treatment (The QuickStart Study)Pivotal-lookingStatus unknown
Macfarlane Burnet Institute for Medical Research and Public Health LtdAcademic, hospital or other
NCT05016609 · 1,800 participants (planned) · Start Mar 9, 2022 · Primary completion Apr 2024
Drug: Sofosbuvir/Velpatasvir (Gilead) · For: Hepatitis C
Sites: Clayton South, Australia; Collingwood, Australia; Corio, Australia · 6 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue197
- headache134
- treatment failure115
- drug ineffective108
- nausea104
- hepatitis c91
- diarrhoea86
- vomiting36
- insomnia29
- abdominal discomfort23
- hepatocellular carcinoma22
- product dose omission20
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2017 | 80 |
| 2018 | 363 |
| 2019 | 275 |
| 2020 | 133 |
| 2021 | 72 |
| 2022 | 46 |
| 2023 | 40 |
| 2024 | 19 |
| 2025 | 43 |
| 2026 | 15 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Vosevi (Sofosbuvir/Velpatas/Voxilaprev)
2024 spending
$45.2M
Beneficiaries
711
1,849 claims
Per beneficiary
$63,513
$857.57 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $67,125,607 |
| 2021 | $58,255,793 |
| 2022 | $49,927,569 |
| 2023 | $46,336,417 |
| 2024 | $45,158,008 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Drug-associated pulmonary arterial hypertension.
McGee M, Whitehead N, Martin J, et al. · Clin Toxicol (Phila) 2018 · Systematic Review
- Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SARS-CoV-2 infection.
Sokhela S, Bosch B, Hill A, et al. · J Antimicrob Chemother 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Bioequivalence Study of Velpatasvir/Sofosbuvir Oral Coated Tablets in Healthy Volunteers Under Fasting Conditions.
Noskov S, Arefeva A, Radaeva K, et al. · Clin Pharmacol Drug Dev 2024 · Randomized Controlled Trial, Comparative Study
- Sofosbuvir-velpatasvir in children 3-17 years old with hepatitis C virus infection.
Jonas MM, Romero R, Rosenthal P, et al. · J Pediatr Gastroenterol Nutr 2024 · Multicenter Study, Clinical Trial, Phase II
- Cardiac Harms of Sofosbuvir: Systematic Review and Meta-Analysis.
Caldeira D, Rodrigues FB, Duarte MM, et al. · Drug Saf 2018 · Meta-Analysis, Systematic Review
- Cost-effectiveness of treating hepatitis C in Seychelles.
Adeline NJF, Geue C, Hermami MR · Pan Afr Med J 2019 · Systematic Review
Sponsor: Gilead Sciences
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.